Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine adjunct to ECT for depression
NCT04661475Phase 4Unknown
- Sponsor
- Sultan Qaboos University
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) comparing Dexmedetomidine + ECT with Placebo + ECT (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale at 3 weeks. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04661475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661475.